HIL awarded €2.5M in grant funding by the EU

The European Commission managing Horizon 2020 – the EU Framework Programme for Research and Innovation – today approved HIL’s Phase-II proposal, at a total budget of €3.3M. The positive funding decision, under Horizon 2020 SME instrument, followed an extensive review process, culminating in an in-person pitch by HIL’s senior leadership team in front of a panel of judges in Brussels a few weeks ago. HIL’s vision, execution capabilities and international partnerships passed with flying colors all of Horizon 2020’s assessment thresholds for the award criteria – excellence, impact, innovation, quality and efficiency of implementation. The new grant will help HIL further advance the development of its innovative Proton Therapy solutions, towards commercialization.

Horizon 2020 is the biggest EU Research and Innovation programme ever, and one of the most competitive. It’s aim is to foster breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.